Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old

• Published in: Radiation oncology (London, England) England), 2017-07, Vol.12 (1), p.112-112, Article 112
• Main Authors: Hayashi, Yuichiro, Mitsudo, Kenji, Sakuma, Kaname, Iida, Masaki, Iwai, Toshinori, Nakashima, Hideyuki, Okamoto, Yoshiyuki, Koizumi, Toshiyuki, Oguri, Senri, Hirota, Makoto, Kioi, Mitomu, Koike, Izumi, Hata, Masaharu, Tohnai, Iwai
• Format: Article
• Language: English
• Subjects: Age; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biocompatibility; Biomedical materials; Cancer therapies; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Care and treatment; Chemoradiotherapy; Chemotherapy; Cisplatin; Cisplatin - therapeutic use; Clinical outcomes; Dermatitis; Elderly patient; Female; Follow-Up Studies; Geriatrics; Head & neck cancer; Head and neck cancer; Humans; Intra-arterial chemotherapy; Intubation; Jaw; Lymphatic system; Male; Metastasis; Mouth Neoplasms - pathology; Mouth Neoplasms - therapy; Mucositis; Neutropenia; Older people; Oral cancer; Oral squamous cell carcinoma; Osteoradionecrosis; Patient outcomes; Patients; Prognosis; Quality; Quality of life; Radiation therapy; Radiotherapy; Retrospective Studies; Squamous cell carcinoma; Survival; Survival Rate; Toxicity; Tumors; Veins & arteries
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-017-0847-3

The aim of this retrospective observational study was to evaluate toxicities, overall survival, and locoregional control in elderly oral squamous cell carcinoma patients who had undergone retrograde intra-arterial chemotherapy combined with radiotherapy. Thirty-one elderly patients over 80 years old with oral squamous cell carcinoma were enrolled in present study. The treatment schedule consisted of intra- arterial chemotherapy (docetaxel, total 60 mg/m ; cisplatin, total 150 mg/m ) and daily concurrent radiotherapy (total, 60 Gy) for 6 weeks. The median patient age was 82.5 years old (range, 80-88 years). Of the 31 patients, six (19%) had stage II, 6 (19%) had stage III, 17 (55%) had stage IVA, and 2 (6%) had stage IVB. The median follow-up period for all patients was 37 months (range, 7-86 months). The 3-year overall survival and locoregional control rates were 78% and 81%, respectively. The major acute grade 3 adverse events were oral mucositis in 22 (71%) patients, neutropenia in 16 (52%), and dermatitis in 11 (35%). With respect to late toxicities, 1 patient (3%) developed grade 3 osteoradionecrosis of the jaw. No grade 4 or higher toxicities were observed during the treatment and follow-up periods. Retrograde intra-arterial chemotherapy combined with radiotherapy was effective in improving overall survival and locoregional control even for elderly patients.